EXAGEN INC. (XGN) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, EXAGEN INC.'s filing signal turned positive.

Exagen Inc. is a medical technology company specializing in the development and commercialization of innovative diagnostic testing products under its AVISE(R) brand, primarily targeting complex rheumatic and autoimmune diseases like Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA). The company's flagship product, AVISE(R) CTD, which accounted for 91% of revenue in 2025, aids in the differential diagnosis of these conditions by utilizing proprietary biomarkers. Exagen focuses on the U.S. market, targeting approximately 6,000 rheumatologists with its specialized sales force. The company has undergone an operational turnaround, achieving revenue growth and gross margin expansion while reducing operating expenses and cash burn. Exagen aims to become a partner of choice for healthcare providers and payors by improving patient outcomes through advanced diagnostic solutions.

Revenue is primarily driven by the sale of its AVISE(R) CTD testing product, which represents the vast majority of its revenue. Growth is also influenced by testing volume and average selling price (ASP) expansion, supported by the addition of new biomarkers and disciplined payer engagement.